Effect of raloxifene on invasive breast cancer incidence in postmenopausal women stratified by Gail risk assessment: Results of the Continuing Outcomes Relevant to Evista (CORE) trial
| Autor: | Elizabeth Barrett-Connor, T. J. Powles, Steve Cummings, D. Disch, Silvana Martino, Jane A. Cauley, John L. Mershon, R. J. Secrest |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Gynecology
Oncology Cancer Research medicine.medical_specialty Core (anatomy) Postmenopausal women business.industry Incidence (epidemiology) Osteoporosis medicine.disease Placebo Breast cancer Internal medicine medicine Raloxifene skin and connective tissue diseases Risk assessment business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 22:1018-1018 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | 1018 Background: Raloxifene (RLX) is approved for prevention and treatment of postmenopausal osteoporosis. Breast cancer incidence was a secondary outcome of the Multiple Outcomes of Raloxifene (MORE) trial; compared to placebo (Plc), invasive breast cancer (IBC) incidence was reduced 72% in postmenopausal women with osteoporosis receiving RLX for 4 yrs. Methods: The CORE trial, a double-blind 4-yr follow-up to MORE, examined the long-term effect of RLX on IBC incidence. All MORE participants were eligible for CORE. Information needed to assess breast cancer risk using the Gail model was not collected until the start of CORE. This pre-specified secondary CORE analysis examined the effect of RLX on incidence of IBC in women classified at low ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|